science

Could it be the first one to pass this test phase?

To study the safety of YCT-529 in humans, we conducted a Phase 1a clinical trial where 16 healthy men received either placebo or escalating single doses of YCT-529 to assess its safety and tolerability. YCT-529 was well tolerated, and no adverse effects were noted. The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT-529 for 28 days and 90 days, to study safety and changes in sperm parameters.